A comprehensive view of Novartis AG. This page highlights a small sample of our full coverage.
For real-time access, please log in to your R&D/Patents Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

Novartis reports 78.8% of multiple sclerosis patients given continuous treatment with injectable drug Kesimpta ofatumumab have no relapse, worsening or condition, disease activity after four years of treatment; Kesimpta had sales of US$195M in Q1

FDA grants accelerated approval for oral Tafinlar dabrafenib and Mekinist trametinib from Novartis to treat unresectable or metastatic solid tumors with BRAF V600E mutation in adult, pediatric patients; BRAF V600E accounts for 90% of BRAF-mutant cancers

Health Canada approves Novartis’ Tabrecta capmatinib tablets to treat adults with locally advanced unresectable or metastatic non-small cell lung cancer; NSCLC is most common type of lung cancer, will affect 30,000 Canadians in 2022

Novartis seeks to grow contract development, manufacturing unit with 15 biotech, cell, gene facilities in US, Europe, Asia; CDMO unit offers microbial fermentation, container filling, global packaging logistics, viral vector production, other services

Novartis reports combination of Kisqali ribociclib and fulvestrant offer survival benefit of almost 16 months in previously untreated breast cancer versus fulvestrant alone; Kisqali is approved in more than 95 countries to treat breast cancer

Ask us about our R&D/Patents market view

Trending Chart

Interactive chart with headline count